PROS1 and COVID-19: Given the high sequence similarity and sequence identity between ACE and ACE2 [18], and the reported reduced risk of mortality and disease associated with use of ACE inhibitors among COVID-19 patients [55,56,57], investigating the ability of ACE inhibitors to block ACE2 interaction with the SARS-CoV-2 S protein would be promising.